目的 探討腎康注射液聯(lián)合左西孟旦治療冠狀動脈搭橋術(shù)后早期急性腎損傷的臨床效果。方法 收集2011年3月—2016年7月在安陽市人民醫(yī)院接受診治的冠狀動脈搭橋術(shù)后急性腎損傷患者122例，隨機分為對照組（61例）和治療組（61例）。對照組患者靜脈注射左西孟旦注射液，初始劑量10 μg/kg，持續(xù)10 min，此后以0.1~0.2 μg/（kg·min）的速度持續(xù)23 h。治療組在對照組的基礎(chǔ)上靜脈滴注腎康注射液，10 mL加到5%葡萄糖注射液100 mL中，1次/d。兩組患者均連續(xù)治療7 d。評價兩組患者臨床療效，同時比較兩組患者治療前后24 h尿蛋白、尿微量白蛋白、血清尿素氮、血肌酐和腎小球濾過率（GFR）變化。結(jié)果 治療后，對照組和治療組的總有效率分別為70.49%、85.25%，兩組比較差異有統(tǒng)計學(xué)意義（P < 0.05）。治療后，治療組患者24 h尿蛋白和尿微量白蛋白均比治療前顯著下降，同組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）；且治療后治療組患者24 h尿蛋白和尿微量白蛋白水平優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。治療后，兩組患者血尿素氮、血肌酐均較治療前顯著降低，兩組GFR顯著升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P < 0.05）；且治療后治療組患者尿素氮、血肌酐和GFR水平均優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。結(jié)論 腎康注射液聯(lián)合左西孟旦治療冠狀動脈搭橋術(shù)后急性腎損傷療效確切，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Shenkang Injection combined with levosimendan in treatment of early acute renal injury after bypass operation of coronary artery. Methods Patients (122 cases) with early acute renal injury after bypass operation of coronary artery in the People's Hospital of Anyang from March 2011 to July 2016 were randomly divided into control (61 cases) and treatment (61 cases) groups. Patients in the control group were iv administered with Levosimendan Injection, the initial dosage was 10 μg/kg for 10 min, then at the rate of 0.1 — 0.2 μg/(kg·min) for 23 h. Patients in the treatment group were iv administered with Shenkang Injection on the basis of the control group, 10 mL added into 5% glucose injection 100 mL, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the change of 24 h urinary protein, urinary microalbumin, serum urea nitrogen and creatinine in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 70.49% and 85.25% respectively, and there was difference between two groups (P < 0.05). After treatment, the 24 h urinary protein and urinary microalbumin in the treatment group were significantly decreased, the difference was statistically significant in the same group (P < 0.05). And the 24 h urinary protein and urinary microalbumin in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, blood urea nitrogen and serum creatinine in two groups were significantly decreased, but GFR in two groups was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And after treatment the serum urea nitrogen, creatinine and GFR in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusions Shenkang Injection combined with levosimendan has a significant curative effect in treatment of early acute renal injury after bypass operation of coronary artery, which has a certain clinical application value.